Solventum Corp. (SOLV) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.

Total Cash From Operating Activities Chart for Solventum Corp.

Solventum Corp. (SOLV) operating cash flow for FY2025 was USD 369.0M, a -68.9% change from FY2024. Solventum Corp.'s operating cash flow grew from USD 2.0B in 2020 to USD 369.0M in 2025 (-81.8% over 5 years). Operating cash flow compound annual growth rate: 5-year CAGR of -28.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$14.12B
Implied Share Price
$82.96
Enterprise Value
$19.52B
Revenue (TTM)
$8.26B
EBITDA
$1.12B
Profit Margin
17.33%
Trailing P/E
10.70
Forward P/E
13.04
Price/Book (MRQ)
2.98
Price/Sales (TTM)
1.71
EV/EBITDA
7.84
EV/Revenue
2.36
Dividend Yield
—
Book Value
$28.64
Free Cash Flow (FY2025)
-$10.00M
Free Cash Flow Yield
-0.07%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.